For conditions where runaway inflammation is the dominant pathology ulcerative colitis at a cellular level, for example BPC-157 alone may not fully address the inflammatory mechanism
What are your impressions?
Baksh et al., Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study, Sci
For those exploring peptides for gut health , understanding GI side effects from GLP-1 agonists is particularly relevant, as the mechanisms overlap significantly
In clinical use, many patients report reduced appetite, less snacking, smaller portion sizes, and fewer cravings for calorie-dense foods
A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain